argenx NV ADR (ARGX)vsJasper Therapeutics Inc (JSPR)
ARGX
argenx NV ADR
$872.58
-1.13%
HEALTHCARE · Cap: $54.24B
JSPR
Jasper Therapeutics Inc
$0.62
+3.45%
HEALTHCARE · Cap: $22.91M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
JSPR
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$872.58
$1555.11 discount
Intrinsic value data unavailable for JSPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 184.5x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : JSPR
The strongest argument for JSPR centers on Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : JSPR
The primary concerns for JSPR are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while JSPR is a value play — different risk/reward profiles.
JSPR carries more volatility with a beta of 3.07 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 19/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Jasper Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for patients suffering from severe conditions such as sickle cell disease and specific hematologic malignancies. Leveraging state-of-the-art technologies, Jasper seeks to minimize transplant-related complications, addressing critical unmet needs in the hematology and oncology fields. Supported by a robust intellectual property portfolio and strategic collaborations, the company is well-positioned to drive innovation and propel its clinical pipeline forward, underscoring its commitment to transformative solutions in regenerative medicine.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?